LIfT Biosciences Ltd is a Biotech start-up bringing a 1st in class Immuno-Oncology Cell Therapy to market that builds on 18 years of ground breaking research into innate cancer immunity and Leukocyte Infusion Therapy (LIfT). LIfT as a medical procedure has already proven to be curative in mice and with promising human data in an FDA approved small proof-of-concept study showing 40-80% tumour necrosis.
In October 2017, LIfT BioSciences stunned the world as they produced N-LIfT: ‘The World’s First Ever Neutrophils Ex-vivo from stem cells to Demonstrate Super (selective) Cancer Killing Ability’, and was given first-in-class status by the EMA as an ATMP. N-LIfT is a therapeutic platform that overcomes significant commercial and medical barriers to bringing LIfT to market, transforming a potentially effective but unscalable medical procedure into a potentially scalable and patented product that safely and consistently destroys solid tumours that other therapies can not.
Our vision is to develop the world’s first cell bank of ‘cancer killing neutrophils’ to deliver a portfolio of immuno-oncology cell therapies for all solid tumours, with an initial focus on rare tumours such as NSCLC, liver, ST sarcoma & pancreatic cancer.
We are now seeking syndicate partners for our Series A POC Clinical Trial, and co-development partners for commercialisation.
In October 2017, LIfT BioSciences stunned the world as they produced N-LIfT: ‘The World’s First Ever Neutrophils Ex-vivo from stem cells to Demonstrate Super (selective) Cancer Killing Ability’, and was given first-in-class status by the EMA as an ATMP. N-LIfT is a therapeutic platform that overcomes significant commercial and medical barriers to bringing LIfT to market, transforming a potentially effective but unscalable medical procedure into a potentially scalable and patented product that safely and consistently destroys solid tumours that other therapies can not.
Our vision is to develop the world’s first cell bank of ‘cancer killing neutrophils’ to deliver a portfolio of immuno-oncology cell therapies for all solid tumours, with an initial focus on rare tumours such as NSCLC, liver, ST sarcoma & pancreatic cancer.
We are now seeking syndicate partners for our Series A POC Clinical Trial, and co-development partners for commercialisation.
Location: Ireland
Employees: 11-50
Total raised: $14.03M
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | MassChalle... | masschalle... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.07.2025 | Grant | $14.03M | - |
Mentions in press and media 12
| Date | Title | Description |
| 30.07.2025 | BioTech Secures Landmark Funding For Cancer Breakthrough | LIfT BioSciences, a pioneering biotech, secured a groundbreaking €12 million grant. This major funding fuels first-in-human clinical trials for IMANs, their novel cancer immunotherapy. IMANs are designed to defeat tenacious treatment-resist... |
| 30.07.2025 | LIfT BioSciences Receives €12M Grant | LIfT BioSciences, a London, UK- and Galway, Ireland-based rapidly emerging biotech and the global leader in neutrophil immunotherapies, received €12M in Grant from Ireland’s Disruptive Technologies Innovation Fund (DTIF). The company intend... |
| 29.07.2025 | London-based LIfT BioSciences secures €12 million to ovecome treatment resistance in solid tumours | LIfT BioSciences, a British/Irish BioTech focused on neutrophil immunotherapies, today announces a grant of €12 million has been awarded from Ireland’s Disruptive Technologies Innovation Fund (DTIF) to advance its Immuno-Modulatory Alpha Ne... |
| 29.07.2025 | LIfT BioSciences lands record €12M grant to launch human cancer trials | Irish Immunotherapy startup LIfT BioSciences, has secured a €12 million grant from Ireland’s Disruptive Technologies Innovation Fund (DTIF) to support the first human trial of its breakthrough cancer therapy. Unlike many cancer treatments t... |
| 18.11.2024 | LIfT BioSciences expands into Ireland for manufacturing & clinical operations | LIfT BioSciences expands into Ireland for manufacturing & clinical operations London, 18 November 2024– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company preparing to start clinical trials for its first-in-... |
| 18.11.2024 | LIfT BioSciences expands into Ireland for manufacturing & clinical operations | LIfT BioSciences expands into Ireland for manufacturing & clinical operations London, 18 November 2024– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company preparing to start clinical trials for its first-in-... |
| 01.07.2024 | LIfT BioSciences appoints Antonin (Tony) de Fougerolles as Chairman of its Board of Directors | LIfT BioSciences appoints Antonin (Tony) de Fougerolles as Chairman of its Board of Directors London, 1 July 2024– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company preparing to start clinical trials for its fi... |
| 24.05.2024 | Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting | Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting London, 24 May 2024 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company about to start clinica... |
| 19.12.2022 | LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS | /EIN News/ -- LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS Additional investment supports plans for N-LIfT to enter the clinic by Q1 2024 London, 19 December 2022 – LIfT BioSciences... |
| 14.09.2022 | LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models | LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models London, 14th September 2022 – LIfT BioSciences today announced that its first-in-class cell therapy... |
Show more